Currently out of the existing stock ratings of Uy Ear, 24 are a HOLD (32.88%), 49 are a BUY (67.12%).

Uy Ear

Work Performance Price Targets & Ratings Chart

Analyst Uy Ear, currently employed at MIZUHO, carries an average stock price target met ratio of 41.2% that have a potential upside of 23.44% achieved within 186 days.

Uy Ear’s has documented 139 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARQT, Arcutis Biotherapeutics at 26-Feb-2025.

Wall Street Analyst Uy Ear

Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 1/3/2024. The price target of $8 was fulfilled within 44 days with a profit of $4.09 (104.6%) receiving and performance score of 23.77.

Average potential price target upside

of $35.14 (31.1%) on SRPT (SAREPTA THERAPEUTICS).
of $10.37 (42.57%) on ALKS (ALKERMES PLC).
of $9.13 (8.53%) on NBIX (NEUROCRINE BIOSCIENCES).

ARQT Arcutis Biotherapeutics AVRO AVROBIO NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc EOLS Evolus OCGN Ocugen SELB Selecta Biosciences SRPT Sarepta Therapeutics RVNC Revance The QURE Uniqure NV SAGE Sage Therapeutic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jonathan Block (GOLDMAN SACHS)